linjc16/ctgov huggingface dataset:
3-midline-ports Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
The 3-midline-ports technique is a safety approach and associates lower postoperative pain, when compared with the standard French technique.

Detailed Description
-----------------
The patients will be randomized into 2 groups: those patients undergoing laparoscopic cholecystectomy following the French technique (Group 1) and those ones undergoing the 3-midline-ports approach (Group 2).

Official Title
-----------------
Three Ports Placed in the Line Alba of the Abdomen (3-midline-ports Technique): an Alternative Approach for Laparoscopic Cholecystectomy

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Procedure: 3-midline-ports laparoscopic cholecystectomy
* Procedure: 3-midline-ports laparoscopic cholecystectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing elective cholecystectomy for symptomatic gallstones. Exclusion Criteria: Diagnosis of acute cholecystitis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: 3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.|
|Procedure: 3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain | The postoperative pain will be investigated 24 hours after surgery | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laparoscopic cholecystectomy, Postoperative pain
A Study of Flap Thickness Results Using the Carriazo Pendular Microkeratome - 130 Micrometers Head.

Study Overview
=================
Brief Summary
-----------------
A study of flap thickness predictability in patients submitted to Laser in Situ Keratomileusis (LASIK) with the Carriazo-Pendular microkeratome (130 micrometers head size).

Official Title
-----------------
LASIK Flap Thickness Predictability With the Carriazo Pendular Microkeratome

Conditions
-----------------
Corneal Flap Thickness (Micrometers)

Intervention / Treatment
-----------------
* Device: Carriazo Pendular microkeratome


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: LASIK candidates treated with the Carriazo-Pendular microkeratome - 130 micron head Exclusion Criteria: corneal irregularities > 3D Thin corneal CCT < 460μm Active anterior segment disease Previous intraocular or corneal surgery History of herpetic eye disease Corneal scarring Glaucoma Severe dry eye Topographic evidence of keratoconus
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Carriazo Pendular microkeratome|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal flap thickness (micrometers) | Flap thickness was calculated by subtracting the preoperative central corneal thickness minus the intraoperative residual stromal thickness. All measurements were made using ultrasound pachymetry (non-interventional technique). | 6 months postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Flap, LASIK, Corneal
Reliability and Validity of a New Device Measuring Spinal Rotation on the Transverse Plane

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to investigate the reliability and validity of a new device similar to a scoliometer. The intended name of the device will be Scolioscope

Detailed Description
-----------------
Οne cohort of participants will be used and the reliability of the equipment will be used to test/retest the repeatability of the measurements The validity will be measured against a gold standard for measuring angles

Official Title
-----------------
Reliability and Validity of a New Device Measuring Spinal Rotation on the Transverse Plane

Conditions
-----------------
Scoliosis

Intervention / Treatment
-----------------
* Device: Scoliometer (scolioscope)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: lumbar and thoracic scoliosis - Exclusion Criteria: recent spinal surgery, cancer, spinal fixation -

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Scoliometer (scolioscope)|Individuals with scoliosis will participate in this study. The device will be used to determine spinal rotation on the transverse plane. Repeated measures will be taken.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reliability | Reliability of device on repeated measures both intra and inter observer | 2021-2022 | 
| Validity | Validity of device will be measured | 2021-2022 |
Extended Follow-Up Study for Subjects Who Participated in 2010 Study

Study Overview
=================
Brief Summary
-----------------
This study is being performed to follow up on subjects who participated in the initial study (ZA10-001) in 2010.

Detailed Description
-----------------
The primary objective of this investigation is to assess the durability of treatment outcomes with the ZELTIQ System.

Official Title
-----------------
Non-Invasive Reduction of Abdominal Fat Utilizing the JUNO Applicator

Conditions
-----------------
Body Fat Disorder

Intervention / Treatment
-----------------
* Device: The Zeltiq System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject participated in the ZA10-001 study, and received all study treatments. Subject has read and signed a written informed consent form. Exclusion Criteria: Subject has had any surgical or aesthetic procedure(s) in or around the abdomen since the completion of the ZA10-001 study treatments. Subject is pregnant. Subject is unable or unwilling to comply with the study requirements. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the integrity of the data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Independent Photo Review | The primary effectiveness endpoint is the correct identification of the series of pre-treatment images by the three reviewers. | 12+ mos post treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Access reduction | Reduction in the fat layer thickness | 12+ mos post treatment | 
| Subject Satisfaction | Subject satisfaction with the Zeltiq procedure as determined by the results of a subjects satisfaction questionnaire at the follow up visit. | 12+ mos post treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lipolysis, Cryolipolysis, Fat Reduction
A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics

Study Overview
=================
Brief Summary
-----------------
As one of the most common malignant tumors in women, the incidence of ovarian cancer is expected to increase year by year. Due to its lack of typical symptoms and effective screening methods, and the characteristics of implantation and distant metastasis, more than 70% of ovarian cancers were in the metastatic stage at the time of diagnosis. In this study, the investigators will collect large samples of tissue from patients with ovarian cancer, conduct multi-omics studies, and mapped the characteristic maps of the genome and transcriptome of patients with metastatic ovarian cancer, and explore the molecular mechanisms that can be used as new targets for the treatment of ovarian cancer. Besides, the investigators will design and establish a database of metastatic ovarian cancer, integrate multiple omics, imaging, pathology, and clinical information to study their potential relevance, and analyze the relationship between various omics, imaging, pathology, and prognosis, establish ovaries Cancer prediction model.

Official Title
-----------------
A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics

Conditions
-----------------
Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female, ≥18 years old; diagnosed as ovarian cancer by imaging and pathology; did not receive any anti-tumor drug treatment before surgery in the gynecology clinical department of the Sun Yat Sen Memorial Hospital of Sun Yat-Sen University; received ovarian cancer surgery and Follow-up treatment; Patients voluntarily participate in the research of this subject, have good compliance, and can complete the enrollment by the requirements of the trial; Sign informed consent and agree to the collection and use of their data. Exclusion Criteria: Patients who have received other anti-tumor treatments or received tumor surgery before enrollment; Patients with malignant tumors in other parts; Patients with uncontrollable neurological, psychiatric, or mental disorders; Poor compliance and inability to Cooperate and describe treatment responders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-Free-Survival |  | The sample will be tested immediately after they are taken from patients and the statistical analysis will be taken through study completion, an average of 3 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multi-omics, ovarian cancer
Prognostic Measures in Ambulatory Care Settings

Study Overview
=================
Brief Summary
-----------------
The primary objective of this prospective study is to develop a new method of classifying the prognosis of ambulatory patients according to their risk of long term mortality, institutionalization, morbidity (including the deterioration of pre-existing conditions or development of new problems) and functional deterioration.

Detailed Description
-----------------
Specifically, from a random sample of 2000 patients taken from a cohort of established patients followed for at least three years in a general medicine practice, the objectives are: to identify the demographic, clinical, and functional status variable that predict the risk of death, morbid events (e.g., the development of new complications or deterioration of existing conditions), or the deterioration in functional status using a half of the cohort chosen at random; to combine these findings into a prognostic scale that can be employed in routine clinical practice; and to validate the performance of this scale in the second half of the cohort. There are no interventions in this study. Patients already under medical care by Cornell physicians will be enrolled. The only requirements for patients are to complete the questionnaires on an annual basis.

Official Title
-----------------
Prognostic Measures in Ambulatory Care Settings

Conditions
-----------------
General Internal Medicine Patients

Intervention / Treatment
-----------------
* Behavioral: There are no interventions in this study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Patients who are currently under the care of Physicians at Cornell Internal Medicine Associates. Exclusion Criteria: Patients who do not wish to participate in the study. Patients who are not able to provide informed written consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: There are no interventions in this study|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To develop a new method of classifying the prognosis of ambulatory patients according to their risk of long term mortality, institutionalization, morbidity and functional deterioration. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prognosis, risk of death, morbidity, mortality, quality of life
Tilt of the Intraocular Lens in Patients Undergoing Combined Phacoemulsification and Vitrectomy With Airtamponade

Study Overview
=================
Brief Summary
-----------------
Vitrectomy with membrane peeling has developed to be the gold-standard in treatment of epiretinal membranes. Due to the possibility of vitrectomy induced cataract, in many ophthalmic surgical centers it has become usual to indicate combined phacoemulsification and vitrectomy in case of existing cataract. Epiretinal membranes (ERM) and pseudomaculaforamen are disorders involving the posterior pole of the eyeball with consecutive vision loss. ERM can be well visualized with spectral domain optical coherence tomography (SD-OCT). Different study groups showed that even intraoperative use of SD-OCT is possible.

Detailed Description
-----------------
The aim of the study is to document tilt of the intraocular lens in combined phacoemulsification and vitrectomy by photography of purkinjereflexes. During vitrectomy tamonade with air or saline are regarded as equal in substituting the removed vitreous. In case of airtamponade, air will be resolved within several days. As airtamponade induces more anterior movement of the implanted intraocular lens in the superior parts of the lens, tilt can result. Saline doesn´t have any influence on the intraocular lens.

Official Title
-----------------
Tilt of the Intraocular Lens in Patients Undergoing Combined Phacoemulsification and Vitrectomy With Airtamponade

Conditions
-----------------
Epiretinal Membrane

Intervention / Treatment
-----------------
* Procedure: airtamponade
* Procedure: saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients sheduled for combined phakoemulsification and 23G pars plana vitrectomy Minimum Age of 21 years written informed consent Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: study group air<br>airtamponade | Procedure: airtamponade<br>* airtamponade is applicated in the study group air<br>|
| Sham Comparator: study group saline<br>saline | Procedure: saline<br>* saline is left in the study Group saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative tilt of the IOL is measured with purkinjemetry | airtamponade has the potential to leave postoperative tilt of the IOL | 3 months |
Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 4.

Study Overview
=================
Brief Summary
-----------------
The main objectives of the study are: 1. To unravel the importance of molecular phenotyping in predicting the response to antimicrobial therapy with potential anti-inflammatory potency The investigators have developed a non-invasive technique based on mRNA analysis of induced sputum that enables us to study airway inflammation in detail. This technique forms the basis for our current project based on the following hypotheses: Different molecular asthma phenotypes exist: a Th2 phenotype and a non Th2 phenotype as reported by Woodruff and colleagues (Woodruff PG et al). Sputum mRNA cytokine levels can be used to diagnose Th2 asthma and discriminate this from non-Th2 asthma. Based on our previous research and preliminary data that non-Th2 asthma can be further divided in Th17 asthma and Th1+Th2 asthma; besides these, a fourth group without Th2, Th17 or Th1 characteristics also exist. These subgroups have different responses to anti-microbial therapy with potential anti-inflammatory potency (macrolides).

Official Title
-----------------
Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 4.

Conditions
-----------------
Asthmatic Patients

Intervention / Treatment
-----------------
* Drug: azithromycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: severe asthmatics (GINA step 4 or step 5 (without anti-IgE)) Exclusion Criteria: viral/fungal/bacterial infection +fever (<1 month) asthma exacerbation (<3 months) other respiratory disease (CF, ciliary dyskinesia,bronchiectasis)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: azithromycin<br> | Drug: azithromycin<br>* azithromycin 500 mg 3/week for 3 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sputum cytokine mRNA |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| responsiveness to the medication |  | 3 months |
Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

Study Overview
=================
Brief Summary
-----------------
Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.

Official Title
-----------------
Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

Conditions
-----------------
Lupus Erythematosus, Systemic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: A diagnosis of systemic lupus erythematosus

Ages Eligible for Study
-----------------
Minimum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |